Main Uses and Benefits of Alfuzin

Alfuzin (alfuzosin) is a medication primarily utilized to manage the symptoms of benign prostatic hyperplasia (BPH). This condition involves a non-cancerous enlargement of the prostate gland, which is common in aging men.

Relieving Urinary Symptoms

The prostate gland surrounds the urethra, the tube that carries urine out of the body. When the prostate enlarges, it can compress the urethra and put pressure on the bladder. Alfuzin belongs to a class of drugs known as alpha-1 blockers. It works by relaxing the smooth muscles in the prostate and the neck of the bladder. This relaxation reduces the resistance to urine flow, helping to alleviate several common symptoms:

• Difficulty starting urination: Helps the flow of urine begin more easily.
• Weak urine stream: Improves the force and consistency of the urinary stream.
• Incomplete emptying: Assists the bladder in emptying more fully, reducing the feeling that urine remains after finishing.
• Frequency and urgency: Decreases the constant or sudden need to urinate, including during the night.

Support for Acute Urinary Retention

In some cases, Alfuzin is used as an adjunct therapy for men experiencing acute urinary retention (AUR). This occurs when a person is suddenly unable to urinate at all, often requiring the temporary use of a catheter. The medication may be prescribed to help improve the success of a "trial without catheter," increasing the likelihood that normal urination can resume once the catheter is removed.

Clinical Benefits and Quality of Life

The primary benefit of Alfuzin therapy is the improvement of urinary function and the reduction of discomfort associated with BPH. By managing these chronic symptoms, the medication aims to help individuals maintain their daily routines and improve overall quality of sleep by reducing nighttime disruptions. Unlike some other treatments for prostate enlargement, this medication is designed to act specifically on the uro-genital tract to minimize effects on systemic blood pressure.

Regulatory References

1. NIH MedlinePlus Drug Information

Alfuzin is officially approved for use exclusively in adult men to manage symptoms. Its eligibility is strictly defined by regulatory documents, which establish clear restrictions based on patient history, other medications, and physiological status.

Population	Eligibility Status
Gender/Age	Indicated for adult men only. Not indicated for the pediatric population or women.
Liver Function	Contraindicated in moderate or severe hepatic impairment. Caution advised in mild hepatic impairment.
Kidney Function	Use requires caution in patients with severe renal impairment (creatinine clearance < 30 mL/min).

The medicine is absolutely contraindicated if the patient has a known hypersensitivity to alfuzosin or is currently taking other alpha-1 adrenergic antagonists. It must also be avoided when co-administered with potent CYP3A4 inhibitors (such as ketoconazole or ritonavir), as this significantly increases the drug's concentration. Caution is necessary for patients with pre-existing conditions like congenital or acquired QT prolongation, coronary artery disease, or a history of symptomatic hypotension.

Alfuzin Interactions with other medicines and products

The interaction profile of Alfuzin (Alfuzosin hydrochloride) is defined by regulatory constraints against combinations that significantly increase drug exposure or enhance blood pressure-lowering effects, based on documented official prescribing information.

---

Contraindicated Combinations

The co-administration of Alfuzin is formally prohibited with the following substances due to high risk:

• Other Alpha-1 Adrenergic Receptor Antagonists (other alpha-blockers), due to the potential for severe additive hypotensive effects.
• Potent CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir, itraconazole), as these significantly increase Alfuzosin exposure (up to 3.2-fold in total drug AUC), which raises the risk of adverse reactions.

---

Exposure and Pharmacodynamic Risks

Alfuzosin is primarily metabolized via the CYP3A4 enzyme, which governs its interactions with inhibitors. Caution is required when Alfuzin is co-administered with:

• Antihypertensive Medications and Nitrates: The combination carries an increased risk of hypotension, postural hypotension, and syncope.
• Phosphodiesterase-5 (PDE5) Inhibitors: Increased risk of symptomatic hypotension due to combined vasodilatory effects.

---

Population and Procedural Constraints

• Severe Hepatic Impairment: Use is formally contraindicated in this population due to the anticipated and documented increase in Alfuzosin blood levels.
• Food Requirement: Alfuzin extended-release tablets must be administered with food to ensure adequate and consistent absorption, as specified in regulatory documents.

Alpha-1 Adrenoceptor Antagonism and Pathway Modulation

Alfuzosin operates through competitive antagonism of post-synaptic Alpha-1 adrenoceptors (alpha1-ARs) located on smooth muscle cells. By occupying these receptor sites, the drug functionally inhibits the binding of the natural signaling molecule norepinephrine, thereby interrupting the sympathetic nervous system's command for muscle contraction. This action occurs within the molecular cascade that controls involuntary muscle tension, functionally suppressing the signaling necessary to mobilize intracellular calcium ions for contraction.

---

Decreasing Dynamic Urethral Resistance

The core physiological consequence of this molecular blockade is smooth muscle relaxation within the prostate, prostatic capsule, and bladder neck. This targeted relaxation decreases the muscular pressure and tone exerted on the prostatic urethra, thereby reducing dynamic resistance at the bladder outlet. The resulting physiological effect is the reduction of urethral resistance, leading to an increase in the cross-sectional area of the urethral lumen. The drug demonstrates functional uroselectivity, meaning its physiological impact is preferentially concentrated in the lower urinary tract tissues, despite its affinity for all alpha1-AR subtypes.

Administration Instructions

The following details the standardized use of alfuzosin extended-release tablets.

Alfuzin is an oral medication that must be taken according to a strict daily schedule to ensure appropriate absorption and consistent therapeutic effect.

Usage Rule	Specific Instruction
Dose	One 10 mg extended-release tablet once daily.
Timing	Immediately after the same meal each day.
Handling	The extended-release tablet must be swallowed whole.
Preparation	Do not crush, chew, or divide the tablet.

Procedural Guidelines

Administration with Food

The medication must be taken with food, specifically immediately after the same meal each day. The extent of drug absorption is approximately 50% lower under fasting (empty stomach) conditions. This specific meal requirement is necessary for proper use.

Missed Dose

If a dose is missed, it is recommended not to take a double dose to make up for the missed tablet. The regular dosing schedule should be resumed with the next scheduled dose. There are no general requirements for age-specific dose adjustments in the elderly (e.g., above 65 years), though careful monitoring is utilized for patients with severe kidney or liver impairment.

Research Evidence / Overview of Studies for Alfuzin

Evidence for use in Benign Prostatic Hyperplasia (BPH) Symptoms

Research exploring how symptoms change over time for Benign Prostatic Hyperplasia (BPH) primarily involves short-term Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving adult men diagnosed with symptomatic BPH. Researchers focused on a set of core outcomes related to physical discomfort and functional imbalance, such as the severity of Lower Urinary Tract Symptoms (LUTS) and the Maximum Urinary Flow Rate (Q max).

Findings describe patterns observed in the studies where use of the medication reported measurements of symptom scores and peak urinary flow rates when observed against the placebo groups over the study period. Research explored outcomes related to the overall progression of BPH, focusing on a composite endpoint (a mix of events like symptom worsening or the need for surgery). One major study also used long-term follow-up (up to two years) to research outcomes related to the long-term course of BPH progression.

Evidence for use after Acute Urinary Retention (AUR) due to BPH

Alfuzosin was studied for its use following an episode of Acute Urinary Retention (AUR) related to BPH, a condition associated with acute or disruptive episodes. These were often Randomized Controlled Trials focusing on men who underwent emergency catheter removal. Research explored short-term symptom changes, specifically monitoring the rate of successful Trial Without Catheter (TWOC).

Studies conducted during periods of increased symptom activity reported measurements indicating that research reported measurements of the rate of successful TWOC when compared against the placebo group in the immediate post-catheterization period. Short-term follow-up studies monitored the rates of subsequent BPH-related surgery in the medication group.

What is Still Uncertain About Alfuzosin's Research Record

Research highlights areas where additional study is needed. Firstly, the long-term effects are not fully established beyond two years, as follow-up durations were limited in the primary controlled trials. Secondly, the specific finding that the medication prevents the primary occurrence of Acute Urinary Retention (AUR) is an area where certainty remains restricted or findings were not consistently reported across all available long-term data. Finally, comparative evidence is lacking in extensive, head-to-head, long-term trials directly comparing Alfuzosin with every other alpha-blocker option.

Key Studies & References

1. Public Assessment Report Scientific discussion Alfuzosine HCl Aurobindo 10 mg, prolonged-release tablets (alfuzosin hydrochloride)

Common questions about Alfuzin (FAQ)

---

Q: Can I drink alcohol while taking Alfuzosin?

Official regulatory documents caution that the use of alcohol with Alfuzosin should be limited or avoided. Alcohol can increase the risk of low blood pressure (hypotension), which may potentially cause symptoms like dizziness or fainting, particularly when changing position (known as orthostatic hypotension). The combination may amplify the drug's effect on blood pressure.

---

Q: What if I already have liver problems?

Alfuzosin is contraindicated (not recommended for use) in patients with moderate or severe liver impairment. Because Alfuzosin is processed by the liver, problems with this organ can lead to higher blood concentrations of the drug. Caution is advised for use in patients with mild liver impairment, according to official product information.

---

Q: What are the very rare but serious side effects?

Official information details several rare but clinically significant side effects. These have included Priapism (a persistent, painful erection), new or worsening Angina Pectoris (chest pain), and a severe allergic reaction called Angioedema (swelling of the face, tongue, or throat). The medicine is also associated with Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery.

---

Q: How long does it take for Alfuzosin to start working?

Clinical studies have indicated that improvements in urinary flow rates may be observed within the first 24 hours of treatment. The drug’s concentration in the blood reaches its peak approximately 8 hours after taking the extended-release tablet. Continued daily use, as prescribed, is intended to maintain consistent symptom control.

---

Q: How long do I have to keep taking Alfuzosin?

Alfuzosin is used to manage the symptoms of an enlarged prostate (BPH); it is not a cure for the condition. The medication is intended for continued daily administration as recommended by a healthcare professional. Discontinuing the medication may lead to the return or worsening of BPH symptoms.

---

Q: Does Alfuzosin require a prescription?

Yes, Alfuzosin is classified as a prescription-only medication. Its use is determined and authorized by a licensed healthcare provider as it is a synthetic prescription drug.

---

Q: What should I do with unused Alfuzosin tablets?

Official federal guidance states that unused or expired tablets should be disposed of via a local drug take-back program. If a take-back program is not available, the tablets can be mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a bag, and then discarded with household trash. They should not be flushed down a toilet.

---

Q: What is the chemical structure of Alfuzosin?

Alfuzosin hydrochloride is the active ingredient, and its chemical designation is provided in the official regulatory labeling. It is chemically a quinazoline derivative with an empirical formula of C19 H27 N5 O4 cdot HCl. This information is included in the official labeling for technical completeness.

Storage and Disposal Conditions for Alfuzosin

Official regulations require Alfuzosin extended-release tablets to be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Brief temperature excursions are permitted between 15 C and 30 C (59 F and 86 F). The medication must be kept away from excessive moisture, heat, and direct light to maintain stability.

Child-Safety and Disposal

The tablets must be stored out of the sight and reach of children.

Regarding disposal, official federal guidance mandates that unused or expired Alfuzosin should not be flushed down a toilet or poured down a sink. The preferred method is to utilize a local drug take-back program. If one is unavailable, the medication can be mixed with an undesirable substance, placed in a sealed bag, and discarded with the household trash.